Published in J Exp Med on June 01, 1991
IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 1.95
Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem (2008) 1.88
Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem (2008) 1.80
Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med (1993) 1.73
Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-beta receptor-IgG1 fusion protein. Proc Natl Acad Sci U S A (1996) 1.71
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res (2014) 1.69
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol (2001) 1.64
Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J (1994) 1.52
Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci (1997) 1.24
Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr (2008) 1.24
Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect Immun (2007) 1.17
Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med (1994) 1.16
Physical and functional association of the high affinity immunoglobulin G receptor (Fc gamma RI) with the kinases Hck and Lyn. J Exp Med (1994) 1.16
Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol (2013) 1.14
Immunogenicity of the outer domain of a HIV-1 clade C gp120. Retrovirology (2007) 1.13
Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? MAbs (2010) 1.12
Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem (2012) 1.09
Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates. Blood (2009) 1.09
Structural determinants of unique properties of human IgG4-Fc. J Mol Biol (2013) 1.09
Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci U S A (2009) 1.04
Structure of an isolated unglycosylated antibody C(H)2 domain. Acta Crystallogr D Biol Crystallogr (2008) 1.03
Localization of the binding site for the monocyte immunoglobulin (Ig) A-Fc receptor (CD89) to the domain boundary between Calpha2 and Calpha3 in human IgA1. J Exp Med (1996) 1.03
Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci U S A (1995) 0.98
The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. Immunology (1995) 0.96
IgG4-Related Fibrotic Diseases from an Immunological Perspective: Regulators out of Control? Int J Rheumatol (2012) 0.95
IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs (2010) 0.93
Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3). Mol Cell Proteomics (2015) 0.88
Immunoglobulin subclass determines ability of immunoglobulin (Ig)G to capture and activate neutrophils presented as normal human IgG or disease-associated anti-neutrophil cytoplasm antibody (ANCA)-IgG. Clin Exp Immunol (2011) 0.87
Development of a specific system for targeting protein to metallophilic macrophages. Proc Natl Acad Sci U S A (2004) 0.86
Engineered protease-resistant antibodies with selectable cell-killing functions. J Biol Chem (2013) 0.86
The role of myeloid receptors on murine plasmacytoid dendritic cells in induction of type I interferon. Int Immunopharmacol (2011) 0.85
Human IgG4: a structural perspective. Immunol Rev (2015) 0.85
Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16. J Clin Invest (1995) 0.84
Crystal structure of deglycosylated human IgG4-Fc. Mol Immunol (2014) 0.83
The contribution of allergen-specific IgG to the development of th2-mediated airway inflammation. J Allergy (Cairo) (2012) 0.83
Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H. Proc Natl Acad Sci U S A (1995) 0.83
Collagen induces maturation of human monocyte-derived dendritic cells by signaling through osteoclast-associated receptor. J Immunol (2015) 0.81
Advances in Antibody Design. Annu Rev Biomed Eng (2015) 0.80
IgG4-related disease: case report and literature review. Auto Immun Highlights (2015) 0.77
Development of sandwich dot-ELISA for specific detection of Ochratoxin A and its application on to contaminated cereal grains originating from India. Front Microbiol (2015) 0.77
IgG4 can induce an M2-like phenotype in human monocyte-derived macrophages through FcγRI. MAbs (2014) 0.77
Pseudorabies Virus US3 Protein Kinase Protects Infected Cells from NK Cell-Mediated Lysis via Increased Binding of the Inhibitory NK Cell Receptor CD300a. J Virol (2015) 0.76
Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1. Mol Immunol (2015) 0.75
The role of B-cells in heart failure. Methodist Debakey Cardiovasc J (2013) 0.75
Room temperature structure of human IgG4-Fc from crystals analysed in situ. Mol Immunol (2016) 0.75
A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent. Int J Clin Exp Med (2015) 0.75
Homogeneous immunoconjugates for boron neutron-capture therapy: design, synthesis, and preliminary characterization. Proc Natl Acad Sci U S A (1998) 0.75
Association between IgG4 Autoantibody and Complement Abnormalities in Systemic Lupus Erythematosus. Mediators Inflamm (2016) 0.75
Channel catfish soluble FcmuR binds conserved linear epitopes present on Cmu3 and Cmu4. Mol Immunol (2009) 0.75
Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health. Sci Rep (2017) 0.75
Function and heterogeneity of human Fc receptors for immunoglobulin G. J Clin Invest (1989) 2.04
Characterization of the Fc receptor for IgG on a human macrophage cell line, U937. J Immunol (1980) 2.03
Phagocytosis mediated by three distinct Fc gamma receptor classes on human leukocytes. J Exp Med (1990) 1.89
Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science (1983) 1.78
Polymorphonuclear leukocyte function triggered through the high affinity Fc receptor for monomeric IgG. J Immunol (1987) 1.72
Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells. J Immunol (1987) 1.67
Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc Natl Acad Sci U S A (1984) 1.23
The monocyte binding domain(s) on human immunoglobulin G. Mol Immunol (1984) 1.19
Structure and function of immunoglobulin domains. VIII. An analysis of the structural requirements in human IgG1 for binding to the Fc receptor of human monocytes. J Immunol (1980) 1.07
Fc gamma R-mediated killing by eosinophils. J Immunol (1989) 1.07
Interaction between hybrid mouse monoclonal antibodies and the human high-affinity IgG FcR, huFc gamma RI, on U937. Involvement of only one of the mIgG heavy chains in receptor binding. J Immunol (1989) 1.01
Structural requirements of immunoglobulin G for binding to the Fc gamma receptors of the human tumor cell lines U937, HL-60, ML-1, and K562. J Immunol (1985) 0.90
The valence for ligand of the human mononuclear phagocyte 72 kD high-affinity IgG Fc receptor is one. J Immunol (1986) 0.89
A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene. Cell (1983) 18.86
Detection of specific hybridoma clones by replica immunoadsorption of their secreted antibodies. Proc Natl Acad Sci U S A (1979) 13.60
Natural history of acute coronary heart attacks. A community study. Br Heart J (1972) 8.55
Immunoglobulin gene expression in transformed lymphoid cells. Proc Natl Acad Sci U S A (1983) 5.18
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A (1984) 3.32
Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol (1989) 2.42
Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J (1988) 2.40
Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol (1997) 2.13
Natural history of unstable angina. Lancet (1972) 2.03
A quantitative difference in the immune response between male and female mice. Proc Soc Exp Biol Med (1968) 1.90
Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry (1995) 1.87
Polypeptide products of nonsense mutations. I. Termination fragments from nonsense mutations in the Z gene of the lac operon of Escherichia coli. J Mol Biol (1970) 1.84
Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods (1992) 1.74
Heavy chain-producing variants of a mouse myeloma cell line. J Immunol (1975) 1.73
Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med (1993) 1.73
Prognosis of new and worsening angina pectoris. Br Med J (1976) 1.59
Murine heavy chain disease. Eur J Immunol (1978) 1.50
A comparison of apparent mRNA half-life using kinetic labeling techniques vs decay following administration of transcriptional inhibitors. Anal Biochem (1991) 1.40
Estimation of antibodies specific for dextran. J Immunol (1978) 1.38
Production and properties of chimeric antibody molecules. Methods Enzymol (1989) 1.35
Membrane IgM, IgD, and IgG act as signal transmission molecules in a series of B lymphomas. J Immunol (1986) 1.34
Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol (1997) 1.32
Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res (2000) 1.31
Characterization of the J chain from polymeric immunoglobulins (IgA-IgM-immunological specificity-primary structure). Proc Natl Acad Sci U S A (1972) 1.31
Regulation of immunoglobulin expression in mouse myeloma cells. Cold Spring Harb Symp Quant Biol (1977) 1.28
Different VL and VH germ-line genes are used to produce similar combining sites with specificity for alpha(1----6)dextrans. J Immunol (1987) 1.27
Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins. Proc Natl Acad Sci U S A (1990) 1.26
Myeloma mutant with a novel 3' flanking region: loss of normal sequence and insertion of repetitive elements leads to decreased transcription but normal processing of the alpha heavy-chain gene products. Mol Cell Biol (1986) 1.21
Transfectomas provide novel chimeric antibodies. Science (1985) 1.20
Policy for early discharge after acute myocardial infarction. Br Med J (1980) 1.19
Bone-marrow suppression associated with cimetidine. Ann Intern Med (1979) 1.17
Sequentially derived mutants of the constant region of the heavy chain of murine immunoglobulins. J Immunol (1979) 1.16
Sequences near the 3' secretion-specific polyadenylation site influence levels of secretion-specific and membrane-specific IgG2b mRNA in myeloma cells. Mol Cell Biol (1986) 1.16
Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med (1994) 1.16
Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol (1998) 1.15
Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A. Proc Natl Acad Sci U S A (1987) 1.15
Transfer and expression of immunoglobulin genes. Annu Rev Immunol (1984) 1.15
Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G. J Biol Chem (1999) 1.14
Two alpha heavy chain disease proteins with different genomic deletions demonstrate that nonexpressed alpha heavy chain genes contain methylated bases. Proc Natl Acad Sci U S A (1981) 1.13
Immunochemical characterization of binding sites of hybridoma antibodies specific for alpha (1 leads to 6) linked dextran. Mol Immunol (1982) 1.12
The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med (1991) 1.12
Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J (1991) 1.09
Loss of a consensus splice signal in a mutant immunoglobulin gene eliminates the CH1 domain exon from the mRNA. Mol Cell Biol (1984) 1.09
Ultraviolet-Stimulated KHCO(3) Efflux from Rose Cells: Regulation of Cytoplasmic pH. Plant Physiol (1983) 1.09
The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. J Exp Med (2000) 1.06
Association constants of hybridoma antibodies specific for alpha (1 leads to 6) linked dextran determined by affinity electrophoresis. Mol Immunol (1982) 1.05
The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer (1994) 1.05
Glycosylation of a VH residue of a monoclonal antibody against alpha (1----6) dextran increases its affinity for antigen. J Exp Med (1988) 1.03
Developmental regulation of membrane and secretory Ig gamma 2b mRNA. J Immunol (1989) 1.01
The identification of mouse myeloma cells which have undergone mutations in immunoglobulin production. Soc Gen Physiol Ser (1974) 1.01
Studies on mouse hybridomas secreting IgM or IgA antibodies to alpha(1 to 6)-linked dextran. Mol Immunol (1981) 1.01
Mutational events in mouse myeloma cells. Crit Rev Immunol (1981) 0.99
Sequences of variable regions of hybridoma antibodies to alpha (1----6) dextran in BALB/c and C57BL/6 mice. J Immunol (1985) 0.98
Expression of a VHC kappa chimaeric protein in mouse myeloma cells. Nature (1984) 0.98
Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci U S A (1995) 0.98
Somatically generated mouse myeloma variants synthesizing IgA half-molecules. J Exp Med (1981) 0.97
Monoclonal IgM rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant-region domains 2 and 3. Proc Natl Acad Sci U S A (1992) 0.97
Production of secretory immunoglobulin A by a single mammalian cell. Proc Natl Acad Sci U S A (1997) 0.96
Mapping studies reveal unique epitopes on IgG recognized by rheumatoid arthritis-derived monoclonal rheumatoid factors. J Immunol (1993) 0.96
Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest (1999) 0.96
In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci (1999) 0.95
Appearance of an early "primed state" in mice following the concomitant injections of antigen and specific antiserum. J Immunol (1972) 0.95
Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched, deleted and point-mutated chimeric antibodies. J Immunol Methods (1993) 0.95
A common sequence motif near nonhomologous recombination breakpoints involving Ig sequences. J Immunol (1993) 0.93
Divergence of human alpha-chain constant region gene sequences. A novel recombinant alpha 2 gene. J Immunol (1994) 0.93
Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life. Cancer Res (1998) 0.93
Elimination of N-linked glycosylation sites from the human IgA1 constant region: effects on structure and function. J Immunol (1997) 0.93
A variant of the dextran-binding mouse plasmacytoma J558 with altered glycosylation of its heavy chain and decreased reactivity with polymeric dextran. Biochemistry (1981) 0.93
Formation of hybridoma clones in soft agarose: effect of pH and of medium. Somatic Cell Genet (1980) 0.93
Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol (2000) 0.92
Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization. Mol Immunol (1994) 0.92
Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-->6) dextran antibody. J Immunol (1999) 0.92
Structural requirements for polymeric immunoglobulin assembly and association with J chain. J Biol Chem (1999) 0.91
Alternative splicing patterns in an aberrantly rearranged immunoglobulin kappa-light-chain gene. Proc Natl Acad Sci U S A (1985) 0.91
Chimeric antibodies with 17-1A-derived variable and human constant regions. Hybridoma (1986) 0.91
Residues critical for H-L disulfide bond formation in human IgA1 and IgA2. J Immunol (1996) 0.91
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. Cancer Res (1993) 0.89
Identification and characterization of a myristylated and palmitylated serine/threonine protein kinase. Biochem Biophys Res Commun (1999) 0.87
Site-specific and directional gene replacement mediated by Cre recombinase. J Immunol Methods (2000) 0.87
Functional and pharmacokinetic properties of antibody-avidin fusion proteins. J Immunol (1997) 0.86
Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface. J Biol Chem (2001) 0.85
Repair of postcatheterization femoral pseudoaneurysms by color flow ultrasound guided compression. Am Heart J (1992) 0.85
Heavy-chain mutants derived from gamma 2b mouse myeloma: characterization of heavy-chain messenger ribonucleic acid, proteins, and secretion in delection mutants and messenger ribonucleic acid in gamma2a mutant progeny. Biochemistry (1981) 0.85
Polypeptide products of nonsense mutations. II. Minor fragments produced by nonsense mutations in the z gene of the lactose operon of Escherichia coli. J Mol Biol (1971) 0.85
Recombinant polymeric IgG: an approach to engineering more potent antibodies. Biotechnology (N Y) (1994) 0.85
An analysis of heavy chain glycopeptides of hybridoma antibodies: correlation between antibody specificity and sialic acid content. J Immunol (1981) 0.84
Psychological, topographic EEG, and CT scan correlates of frontal lobe function in schizophrenia. Psychiatry Res (1989) 0.84
Antibody-cytokine fusion proteins: innovative weapons in the war against cancer. Clin Exp Med (2004) 0.84
ICR-191 and ethyl methanesulfonate induced mutagenesis at the immunoglobulin locus in the Y5606 cultured myeloma cell line. Mutat Res (1981) 0.83
Enhanced immunologic sensitization of mice by the simultaneous injection of antigen and specific antiserum. 3. The role of antigen in controlling the immune response elicited with immune complexes. J Immunol (1967) 0.83
Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J Immunol (1995) 0.83
Genetically engineered antibodies: progress and prospects. Crit Rev Immunol (1992) 0.83
A colorimetric-enzymatic microassay for the quantitation of antibody-dependent complement activation. J Immunol Methods (1999) 0.83
Hybrid IgA2/IgG1 antibodies with tailor-made effector functions. Clin Immunol (2001) 0.82
Amino acid substitutions in VH CDR2 change the idiotype but not the antigen-binding of monoclonal antibodies to alpha(1----6)dextrans. J Immunol (1989) 0.82
A mouse myeloma variant with a defect in light chain synthesis. Eur J Immunol (1979) 0.82